Health Condition 1: null- Patients with endothelial dysfunction and coronary artery disease
Conditions
Interventions
Intervention1: Nebivolol 5 mg: Tablet Nebivolol 5 mg od will be given for a period of 4 weeks along with routine anti ischaemic therapy
Control Intervention1: Metoprolol: Metoprolol 50 mg will be give
Sponsors
JIPMER
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Age - 18-75 years 2. Either sex 3. Angiographically proven coronary artery stenosis with >50% block in atleast one of the major arteries or History of acute coronary syndrome 4. Known case of Hypertension
Exclusion criteria
Exclusion criteria: 1. Patients with history of acute coronary syndrome in the preceding three months. 2. Patients already on nebivolol for BP control 3. Uncontrolled hypertension with SBP > 180mm Hg or DBP >90mmHg 4. Patients with left ventricular ejection fraction 5. Patients with coexisting medical illnesses which can interfere with assessment of outcomes 6. Known history of hypersensitivity reaction to nebivolol 7. Pregnant women and lactating women 8. Patients having coexisting illness which are a contra-indication to beta blocker therapy such as asthma, sick sinus syndrome, peripheral vascular disease, variant angina. 9. Marked dyslipidemia 10. Patients unwilling to participate in the study 11. Past history of liver disease, known case of alcohol abuse, or Elevated liver enzymes defined as ALT, AST or ALP greater than thrice the upper limit of normal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of endothelial dysfunction as measured by flow mediated dilatationTimepoint: Baseline and after four weeks of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| MDA, oxidant status, ICAMTimepoint: baseline and after four weeks | — |
Countries
India
Contacts
Public ContactDr Melvin George
JIPMER
Outcome results
None listed